Meeting
2018 ASCO Annual Meeting
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.
Authors
Patricia Villagrasa
SOLTI Breast Cancer Research Group, Barcelona, Spain
Patricia Villagrasa , Aleix Prat , Mafalda Oliveira , Lorena De La Pena , Xavier Gonzalez , Javier Cortes , Sonia Pernas Simon , Jose Rios , Jordi Canes , Eva Ciruelos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02448420
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS1101)
DOI
10.1200/JCO.2018.36.15_suppl.TPS1101
Abstract #
TPS1101
Poster Bd #
181b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2021 ASCO Annual Meeting
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
First Author: Jian Zhang
Poster
2022 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
First Author: Sara A. Hurvitz
Poster
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
First Author: Tom Stinchcombe